MaxCyte, Inc. Pre-Tax Income
MaxCyte, Inc. (MXCT) reported Pre-Tax Income of -$8.87 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-13
- MaxCyte, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$8.87M.
- MaxCyte, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$4.75M.
- MaxCyte, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$9.60M.
- MaxCyte, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$12.42M.
- MaxCyte, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$44.63M.
- MaxCyte, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$41.05M.
- MaxCyte, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$37.92M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.87M 10-Q · filed 2026-08-13 | -$13.62M 10-Q · filed 2026-08-13 | -$23.22M derived: sum of 3 quarters · filed 2026-08-13 | -$35.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$4.75M 10-Q · filed 2026-05-13 | -$14.35M derived: sum of 2 quarters · filed 2026-05-13 | -$26.76M derived: sum of 3 quarters · filed 2026-05-13 | -$39.12M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$9.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$22.01M derived: sum of 2 quarters · filed 2026-03-25 | -$34.37M derived: sum of 3 quarters · filed 2026-08-13 | -$44.63M 10-K · filed 2026-03-25 |
| 2025-09-30 | -$12.42M 10-Q · filed 2025-11-13 | -$24.77M derived: sum of 2 quarters · filed 2026-08-13 | -$35.03M 10-Q · filed 2025-11-13 | -$45.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$12.36M 10-Q · filed 2026-08-13 | -$22.62M 10-Q · filed 2026-08-13 | -$33.22M derived: sum of 3 quarters · filed 2026-08-13 | -$44.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$10.26M 10-Q · filed 2026-05-13 | -$20.86M derived: sum of 2 quarters · filed 2026-05-13 | -$32.41M derived: sum of 3 quarters · filed 2026-05-13 | -$41.79M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$10.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$22.15M derived: sum of 2 quarters · filed 2026-03-25 | -$31.53M derived: sum of 3 quarters · filed 2026-03-25 | -$41.05M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$11.56M 10-Q · filed 2025-11-13 | -$20.93M derived: sum of 2 quarters · filed 2025-11-13 | -$30.46M 10-Q · filed 2025-11-13 | -$35.74M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$9.38M 10-Q · filed 2025-08-06 | -$18.90M 10-Q · filed 2025-08-06 | -$24.18M derived: sum of 3 quarters · filed 2025-08-06 | -$35.43M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$9.53M 10-Q · filed 2025-05-08 | -$14.80M derived: sum of 2 quarters · filed 2025-05-08 | -$26.05M derived: sum of 3 quarters · filed 2025-05-08 | -$36.57M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$16.53M derived: sum of 2 quarters · filed 2025-03-11 | -$27.04M derived: sum of 3 quarters · filed 2025-03-11 | -$37.92M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$11.25M 10-Q · filed 2024-11-06 | -$21.76M derived: sum of 2 quarters · filed 2024-11-06 | -$32.65M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$10.51M 10-Q · filed 2024-08-06 | -$21.39M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$10.88M 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |